LDS/Medical Tests/T-Cell Antigen Receptor, Gamma (TRG@) Gene Rearrangement Analysis for Abnormal Clonality, Amplified Method, Blood

T-Cell Antigen Receptor, Gamma (TRG@) Gene Rearrangement Analysis for Abnormal Clonality, Amplified Method, Blood

The TCRC gene also known as TRG@ is located on the long arm of chromosome 7, at band q14 and encodes the gamma subunit of the T cell antigen receptor (TCR) found on the surface of T cells. The TCR is responsible for recognizing fragments of antigens bound to major histocompatibility complex (MHC) molecules. The gamma locus includes V (variable), J (joining), and C (constant) segments. During T cell development, the gamma chain gene sequence is synthesized by a recombination event at the DNA level joining a V segment with a J segment. The C segment is later joined by splicing at the RNA level. Different V and J segments can recombine to provide a wide range of antigen recognition. The TCR-gene rearrangements, important for normal immune functions, are diverse and serve as a valuable marker to distinguish clonal T-cell proliferations from reactive (polyclonal) processes.

Clonal rearrangement of the T-cell gamma locus may be found in patients with T cell leukemia, T-cell lymphoma and ataxia telangiectasia. Clonality assessment can be performed by Southern blot (SB) analysis and by PCR and are helpful in the diagnostic evaluation of T-cell proliferations. Detection of a clonal or predominant T-cell receptor gene rearrangement typically indicates the presence of a neoplastic T-cell population. This can help to establish the diagnosis of a T-cell lymphoma or to evaluate for residual or recurrent disease after treatment. However, the presence of a clonal T-cell population does not necessarily indicate a neoplastic process. Clonal T-cell populations are particularly likely to occur in settings where there is physiologic restriction of the T-cell repertoire, such as occurs in autoimmune disorders or with normal aging. Conversely, the absence of a TCR clonality does not necessarily exclude the possibility of a T-cell neoplasm. In all cases the results of TCR analysis must be correlated with pathologic, clinical and other supporting (e.g. immunophenotypic) findings in interpreting the results.

  • To diagnose a T-cell lymphoma and T-cell leukemia
  • To determine whether a T-cell population is polyclonal or monoclonal
  • For the identification of minimal residual disease or early recurrence in patients with a previous diagnosis of a T-cell neoplasm

Positive: Clonal T-cell receptor gene rearrangement was detected. Detection of a clonal T-cell receptor gene rearrangement does not necessarily indicate the presence of a T-cell neoplasm. Apparent clonal T-cell populations are particularly likely to occur in settings where there is physiologic restriction of the T-cell repertoire, such as occurs in autoimmune disorders or with normal aging. Therefore, correlation with pathologic, clinical and other supporting (e.g. immunophenotypic) findings is required for final interpretation of these results.

Negative: No clonal T-cell receptor gene rearrangement was detected. Absence of a clonal T-cell receptor gene rearrangement does not necessarily exclude the possibility of a T-cell neoplasm and correlation with pathologic, clinical and other supporting (e.g. immunophenotypic) findings is required for final interpretation of these results.

Results usually reported as: Positive, negative, or indeterminate for a clonal T-cell population

No clonal T-cell receptor gene rearrangement was detected

Restriction fragment length polymorphism, Polymerase Chain Reaction (PCR), Southern blot polymorphism.

Peripheral blood, bone marrow aspirate, Formalin-fixed paraffin-embedded (FFPE) tissue blocks.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 5-7 days
CBC, FISH, lymph node biopsy, T-cell clonality panel (TCRB, TCR) Lymphocyte clonality panel, PCR, Flow cytometry, Cytogenetic analysis, Bone marrow biopsy, LDH, CMP, Uric acid, PET/CT scan with contrast, Skin bioposy (cutaneous disease, CNS cell count and differential, EBV PCR, ALK gene mutation analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login